Milithin (Lithium Carbonate)

Milithin, a lithium carbonate formulation, acts on mood regulation pathways and is used in the management of bipolar disorder and related conditions.

• Bipolar disorder: stabilises mood and reduces the frequency of depressive and manic episodes.
• Mania: controls acute manic symptoms and helps maintain remission.
• Maintenance therapy: supports long‑term mood stability to prevent relapse.

• Lithium carbonate modulates neurotransmitter signaling by inhibiting inositol monophosphatase, which alters phosphatidylinositol signaling cascades. This leads to downstream effects on second messenger systems, ultimately stabilising neuronal excitability and mood regulation in the central nervous system.

Lithium carbonate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Tremor: mild to moderate shaking, often in the hands.
• Increased thirst and urination: polyuria and polydipsia are frequently reported.
• Gastrointestinal upset: nausea, diarrhoea or abdominal discomfort.
• Weight gain: modest increase in body weight over time.

Serious or Rare Side Effects

• Thyroid dysfunction: hypothyroidism requiring monitoring and possible treatment.
• Renal impairment: reduced kidney function that may be irreversible with prolonged use.

When prescribing Milithin, clinicians should consider several safety measures.

• Serum level monitoring: maintain lithium concentrations within the therapeutic window.
• Renal function assessment: evaluate baseline and periodic kidney function.
• Thyroid function assessment: check thyroid hormones before and during therapy.
• Hydration status: advise patients to avoid dehydration and excessive salt loss.
• Elderly patients: use lower doses and monitor closely for toxicity.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Lithium carbonate can interact with various medications, requiring careful management.

Major Interactions (Avoid)

• ACE inhibitors: may increase lithium levels and risk of toxicity.
• NSAIDs: can reduce renal clearance of lithium, raising serum concentrations.
• Thiazide diuretics: potentiate lithium accumulation and toxicity.
• SSRIs: combined use may increase the risk of serotonin syndrome.
• Carbamazepine: may lower lithium levels, reducing efficacy.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may enhance lithium's blood pressure effects.
• Caffeine: can affect lithium excretion and serum levels.
• Other mood stabilizers: may require dose adjustments.
• Diuretics (non‑thiazide): monitor renal function and lithium levels.
• Anticholinergic agents: may exacerbate cognitive side effects.